(2)
DUBLIN, Feb. 16, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adult patients with idiopathic hypersomnia. If approved,
Xywav will be the first and only approved treatment in the U.S. for adults with idiopathic hypersomnia.
Xywav received Fast Track designation by the FDA in September 2020 for the treatment of idiopathic hypersomnia. Jazz was granted rolling submission by FDA for this sNDA in December 2020, permitting the submission of portions of the proposed application as they were completed.
中国最后的原始部落 村寨发生火灾，曾被黄牌警告限期整改 - 未名空间(mitbbs com)
mitbbs.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mitbbs.com Daily Mail and Mail on Sunday newspapers.
中国最后一个原始部落 云南翁丁遭火灾：两个月前刚进行过灭火救援应急演练|沧源|临沧
163.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 163.com Daily Mail and Mail on Sunday newspapers.
中国最后一个原始部落 遭火灾 两月前曾灭火演练
cyol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cyol.com Daily Mail and Mail on Sunday newspapers.